Abstract
Alzheimer’s disease (AD) and dementia in general are age-related diseases with multiple contributing factors, including brain inflammation. Microglia, and specifically those expressing the AD risk gene TREM2, are considered important players in AD, but their exact contribution to pathology remains unclear. In this study, using high-throughput mass cytometry in the 5×FAD mouse model of amyloidosis, we identified senescent microglia that express high levels of TREM2 but also exhibit a distinct signature from TREM2-dependent disease-associated microglia (DAM). This senescent microglial protein signature was found in various mouse models that show cognitive decline, including aging, amyloidosis and tauopathy. TREM2-null mice had fewer microglia with a senescent signature. Treating 5×FAD mice with the senolytic BCL2 family inhibitor ABT-737 reduced senescent microglia, but not the DAM population, and this was accompanied by improved cognition and reduced brain inflammation. Our results suggest a dual and opposite involvement of TREM2 in microglial states, which must be considered when contemplating TREM2 as a therapeutic target in AD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Data to reproduce the figures are available as of the date of publication at https://github.com/noarachmian/Trem2_senescent_microglia (ref. 77).
Any additional information required to reanalyze the data reported in this paper will be available from the lead contact upon reasonable request.
Code availability
The code is available as of the date of publication at https://github.com/noarachmian/Trem2_senescent_microglia (ref. 77).
Any additional information required to reanalyze the data reported in this paper will be available from the lead contact upon reasonable request.
References
De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).
Wyss-Coray, T. & Rogers, J. Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346 (2012).
Pascoal, T. A. et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 27, 1592–1599 (2021).
Moore, Z., Taylor, J. M. & Crack, P. J. The involvement of microglia in Alzheimer’s disease: a new dog in the fight. Br. J. Pharmacol. 176, 3533–3543 (2019).
Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368, 117–127 (2013).
Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 368, 107–116 (2013).
Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670 (2016).
Castellani, G. & Schwartz, M. Immunological features of non-neuronal brain cells: implications for Alzheimer’s disease immunotherapy. Trends Immunol. 41, 794–804 (2020).
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290 (2017).
Karanfilian, L., Tosto, M. G. & Malki, K. The role of TREM2 in Alzheimer’s disease; evidence from transgenic mouse models. Neurobiol. Aging 86, 39–53 (2020).
Ulrich, J. D., Ulland, T. K., Colonna, M. & Holtzman, D. M. Elucidating the role of TREM2 in Alzheimer’s disease. Neuron 94, 237–248 (2017).
Rea, I. M. et al. Age and age-related diseases: role of inflammation triggers and cytokines. Front. Immunol. 9, 586 (2018).
Jaul, E. & Barron, J. Age-related diseases and clinical and public health implications for the 85 years old and over population. Front. Public Health 5, 335 (2017).
Di Micco, R., Krizhanovsky, V., Baker, D. & d’Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22, 75–95 (2021).
Baruch, K. et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89–93 (2014).
Kipnis, J., Cohen, H., Cardon, M., Ziv, Y. & Schwartz, M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl Acad. Sci. USA 101, 8180–8185 (2004).
Ziv, Y. et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9, 268–275 (2006).
Baruch, K. et al. Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology. Nat. Commun. 6, 7967 (2015).
Giunta, B. et al. Inflammaging as a prodrome to Alzheimer’s disease. J. Neuroinflammation 5, 51 (2008).
Oakley, H. et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006).
Rosenmann, H. et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 212, 71–84 (2008).
Palframan, R. T. et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J. Exp. Med. 194, 1361–1374 (2001).
Yang, J., Zhang, L., Yu, C., Yang, X.-F. & Wang, H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark. Res. 2, 1 (2014).
Kamphuis, W., Kooijman, L., Schetters, S., Orre, M. & Hol, E. M. Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer’s disease. Biochim. Biophys. Acta 1862, 1847–1860 (2016).
Carroll, J. A., Striebel, J. F., Baune, C., Chesebro, B. & Race, B. CD11c is not required by microglia to convey neuroprotection after prion infection. PLoS ONE 18, e0293301 (2023).
Hickman, S. E. et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896–1905 (2013).
Haynes, S. E. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 9, 1512–1519 (2006).
Mildner, A., Huang, H., Radke, J., Stenzel, W. & Priller, J. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia 65, 375–387 (2017).
Merino, J. J., Muñetón-Gómez, V., Alvárez, M.-I. & Toledano-Díaz, A. Effects of CX3CR1 and Fractalkine chemokines in amyloid beta clearance and p-tau accumulation in Alzheimerʼs disease (AD) rodent models: is Fractalkine a systemic biomarker for AD? Curr. Alzheimer Res. 13, 403–412 (2016).
Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a–Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).
Burton, D. G. & Krizhanovsky, V. Physiological and pathological consequences of cellular senescence. Cell. Mol. Life Sci. 71, 4373–4386 (2014).
Palmero, I., Pantoja, C. & Serrano, M. p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125–126 (1998).
Freund, A., Patil, C. K. & Campisi, J. p38MAPK is a novel DNA damage response‐independent regulator of the senescence‐associated secretory phenotype. EMBO J. 30, 1536–1548 (2011).
Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642 (2006).
Beauséjour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212–4222 (2003).
Vaziri, H. et al. ATM‐dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post‐translational activation of p53 protein involving poly (ADP‐ribose) polymerase. EMBO J. 16, 6018–6033 (1997).
Mercurio, D. et al. Protein expression of the microglial marker Tmem119 decreases in association with morphological changes and location in a mouse model of traumatic brain injury. Front. Cell. Neurosci. 16, 820127 (2022).
Gisslén, M. et al. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurol. Neuroimmunol. Neuroinflamm. 6, e512 (2018).
Cantoni, C. et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. 129, 429–447 (2015).
Jin, C. et al. A unique type of highly-activated microglia evoking brain inflammation via Mif/Cd74 signaling axis in aged mice. Aging Dis. 12, 2125–2139 (2021).
Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581 (2017).
Gasque, P., Singhrao, S. K., Neal, J. W., Götze, O. & Morgan, B. P. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am. J. Pathol. 150, 31–41 (1997).
Olmos-Alonso, A. et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain 139, 891–907 (2016).
Kopatz, J. et al. Siglec‐h on activated microglia for recognition and engulfment of glioma cells. Glia 61, 1122–1133 (2013).
Jakovljevic, M. et al. Induction of NTPDase1/CD39 by reactive microglia and macrophages is associated with the functional state during EAE. Front. Neurosci. 13, 410 (2019).
Dvir-Szternfeld, R. et al. Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nat. Aging 2, 60–73 (2022).
Wang, Y. et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667–675 (2016).
Bancaro, N. et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell 41, 602–619.e11 (2023).
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).
Safaiyan, S. et al. White matter aging drives microglial diversity. Neuron 109, 1100–1117 (2021).
Ovadya, Y. & Krizhanovsky, V. Strategies targeting cellular senescence. J. Clin. Invest. 128, 1247–1254 (2018).
Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).
Leger, M. et al. Object recognition test in mice. Nat. Protoc. 8, 2531–2537 (2013).
Streit, W. J., Khoshbouei, H. & Bechmann, I. Dystrophic microglia in late‐onset Alzheimer’s disease. Glia 68, 845–854 (2020).
Streit, W. J., Braak, H., Xue, Q.-S. & Bechmann, I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 118, 475–485 (2009).
Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578–582 (2018).
Talma, N., Gerrits, E., Wang, B., Eggen, B. J. & Demaria, M. Identification of distinct and age‐dependent p16High microglia subtypes. Aging Cell 20, e13450 (2021).
Schlepckow, K. et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12, e11227 (2020).
Jain, N., Lewis, C. A., Ulrich, J. D. & Holtzman, D. M. Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading. J. Exp. Med. 220, e20220654 (2023).
Allen, W. E., Blosser, T. R., Sullivan, Z. A., Dulac, C. & Zhuang, X. Molecular and spatial signatures of mouse brain aging at single-cell resolution. Cell 186, 194–208.e18 (2023).
Zhang, P. et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019).
Ben-Yehuda, H. et al. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy. Mol. Neurodegener. 16, 39 (2021).
Zhao, N. & Bu, G. A TREM2 antibody energizes microglia. Nat. Neurosci. 26, 366–369 (2023).
Rachmian, N. & Krizhanovsky, V. Senescent cells in the brain and where to find them. FEBS J. 290, 1256–1266 (2022).
Xing, Z. et al. Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-β accumulation and improves cognition in APP/PS1 mice. Brain Behav. Immun. 91, 128–141 (2021).
Zou, Y. et al. Programmed cell death protein 1 blockade reduces glycogen synthase kinase 3β activity and tau hyperphosphorylation in Alzheimer’s disease mouse models. Front. Cell Dev. Biol. 9, 769229 (2021).
Rosenzweig, N. et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).
Baruch, K. et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 22, 135–137 (2016).
Majewska, J. et al. p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells. Preprint at bioRxiv https://doi.org/10.1101/2023.01.30.524522 (2023).
Wang, T.-W. et al. Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes. Nature 611, 358–364 (2022).
Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170, 649–663 (2017).
Han, G., Spitzer, M. H., Bendall, S. C., Fantl, W. J. & Nolan, G. P. Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry. Nat. Protoc. 13, 2121–2148 (2018).
Bevins, R. A. & Besheer, J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat. Protoc. 1, 1306–1311 (2006).
Björklund, Å. Single RNA-seq data analysis with R: quality control. Github https://nbisweden.github.io/excelerate-scRNAseq/session-qc/Quality_control.html (2019).
Rachmian, N. & Deitch, D. Trem2_senescent_microglia. Github https://github.com/NoaRachmian/Trem2_senescent_microglia (2024).
Acknowledgements
We sincerely thank A. Tsitsou-Kampeli, H. Ben-Yehuda, S. Suzzi, G. Castellani, M. A. Abellanas, L. Roitman, H. Gal, N. Papismadov, Y. Addadi and I. Sher for technical assistance. We also thank all members of the Krizhanovsky laboratory and the Schwartz laboratory for helpful discussions. This study was supported by a grant from the Advanced European Research Council (no. 741744); Israel Science Foundation (ISF) research grant 991/16; ISF–Legacy Heritage Biomedical Science Partnership research grant 1354/15; grants from the Thompson Foundation and the Adelis Foundation (given to M.S.); and by grants from the European Research Council H2020 program (no. 856487), the Weizmann Centers for Research on Positive Neuroscience and Research on Neurodegeneration, the ISF (no. 1626/20), the Deutsche Forschungsgemeinschaft (CRC 1506), the Israel Ministry of Health, the Belle S. and Irving E. Meller Center for the Biology of Aging and the Sagol Institute for Longevity Research (given to V.K.). V.K. is an incumbent of the Georg F. Duckwitz Professorial Chair and the Shimon and Golde Picker–Weizmann Award.
Author information
Authors and Affiliations
Contributions
N.R., M.S. and V.K. conceptualized the project. N.R., M.S. and V.K. planned the experiments. N.R. designed and performed the CyTOF and flow cytometry experiments and the mouse experiments. S.M. performed and analyzed the NOR task. U.C. and N.R. analyzed flow cytometry. U.C. and N.R. injected mice. H.A. analyzed the snRNA-seq data. N.R. and D.D. analyzed the CyTOF results. H.A., D.D. and N.R. performed data analysis. D.E. and N.R. performed and analyzed RT–PCR. N.R., T.C. and T.M.S. established the CyTOF panel. J.M.P.R. established the flow cytometry panel. S.M. and U.C. contributed to the experiment’s performance and experiment design. L.C. organized the mice colonies and performed genotyping. N.R., M.S. and V.K. wrote the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
V.K. is a co-inventor of patents on senolytics and senolytic approaches and is a consultant for Sentaur Bio. None of these interests influenced the data presented in this manuscript. M.S. is a scientific co-founder of ImmunoBrain Checkpoint, which develops anti-PD-L1 to treat Alzheimerʼs disease. The other authors declare no competing interests.
Peer review
Peer review information
Nature Neuroscience thanks Rudolph Tanzi, V. Wee Yong and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Association between ApoE and senescence markers.
(a) Pearson’s correlation between the expression of ApoE with TREM2 and with senescence markers, p16, p19 and p21. Each color represents a different experiment from Fig. 1; the median expression was Z-scored within each experimental group to account for batch identity.
Extended Data Fig. 2 Differential protein expression between disease-associated microglia (DAM) and senescent microglia.
Differentially expressed proteins between by senescent microglia compared to disease-associated microglia. Each dot represents one protein. The horizontal line marks the significance threshold p < 0.0016 after Bonferroni correction). The vertical dashed lines represent two fold differences in expression.
Extended Data Fig. 3 Proportion of CD45+ cells following senolytic treatment with ABT-737.
(a-g) 10-11 month-old female mice, vehicle control (WT, vehicle) (n = 4), compared to 10-11-month-old 5xFAD female mice, vehicle control (5xFAD, vehicle) (n = 5), and 10-11-month-old 5xFAD female mice, treated with ABT-737 (5xFAD, ABT) (n = 4). Quantitative analysis showing percentage of (a) resting microglia; (b) activated microglia; (c) disease associated microglia; (d) senescent microglia; (e) border-associated macrophages; (f) monocytes; and (g) CD11b- cells among the CNS CD45+ cells. Data are presented as mean values +/- SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Fig. 4 Flow cytometry of splenocytes two weeks following ABT-737 treatment.
12.5-13-month-old male mice, vehicle control (WT, vehicle) (n = 7), compared to 12.5-13-month-old 5xFAD male mice, vehicle control (5xFAD, vehicle; n = 7), and 12.5-13-month-old 5xFAD male mice, treated with ABT-737 (5xFAD, ABT; n = 7). (a) Gating strategy. (b-k) Quantitative analysis by flow cytometry; pink and circles represent the WT group, blue and squares represent the 5xFAD vehicle group, and green and triangles represent 5xFAD ABT group (b) Quantitative analysis of B-cell percentage from total CD45+ cells. (c) Quantitative analysis of myeloid cells percentage from total CD45+ cells. (d) Quantitative analysis of monocyte percentage from total CD45+ cells. (e) Quantitative analysis of neutrophil percentage from total CD45+ cells. (f) Quantitative analysis of T-cell percentage from total CD45+ cells. (g) Quantitative analysis of CD4 + T-cell percentage from total CD45+ cells. (h) Quantitative analysis of naïve T-cell percentage from total CD45+ cells. (i) Quantitative analysis of T-effector cell percentage from total CD45+ cells. (j) Quantitative analysis of T-regulatory cell percentage from total CD45+ cells. (k) Quantitative analysis of CD8 + T-cell percentage from total CD45+ cells. Data are presented as mean values +/- SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Fig. 5 Open Field test.
Two cohorts of mice were combined for the analysis. First cohort of mice: 10-11 month-old female mice, vehicle control (WT, vehicle) (n = 5), compared to 10-11-month-old 5xFAD female mice, vehicle control (5xFAD, vehicle; n = 4), and 10-11-month-old 5xFAD female mice, treated with ABT-737 (5xFAD, ABT; n = 5). Second cohort of mice: 10-11-month-old male mice, vehicle control (WT, vehicle; n = 5), compared to 10-11-month-old 5xFAD male and female, vehicle control (5xFAD, vehicle) (n = 5), and 10-11 month-old 5xFAD male and female mice, treated with ABT-737 (5xFAD, ABT) (n = 7). One-way ANOVA was used for the analyses. Locomotor activity and anxiety were assessed in an open field test and (a) distance moved; (b) mean velocity; (c) cumulative duration in the center zone; (d) frequency entering the center zone; and (e) latency until center entry were recorded, P(WT vs. AD vehicle) = 0.0100, P(WT vs. AD ABT) = 0.8283, P(AD vehicle vs. AD ABT) = 0.0125. Data are presented as mean values +/- SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Fig. 6 Mass cytometry gating strategy.
In the analysis workflow, i) we initially selected CD11b as a stable signal over time and applied gating. ii) Subsequently, gating was performed based on event length and Gaussian residual parameters. iii) To eliminate bead-related interference, the 140Ce bead channel was utilized for gating. iv) Next, live single cells were identified using cisplatin in the 195Pt channel, and iridium DNA labeling in the 193Ir channel, and v) the single-cell population was further refined using two iridium channels. vi) Finally, gating was applied to isolate CD45-positive cells.
Supplementary information
Supplementary Table
Supplementary Table 1: differentially expressed genes of each cluster.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rachmian, N., Medina, S., Cherqui, U. et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer’s disease model mouse brain. Nat Neurosci (2024). https://doi.org/10.1038/s41593-024-01620-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41593-024-01620-8